---
layout: default
title: Flunisolide
parent: 僅模型預測 (L5)
nav_order: 717
evidence_level: L5
indication_count: 10
---

# Flunisolide
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

Using the report-writing instructions given directly in the prompt (this is a fully self-contained task specification, not a coding/debugging task requiring another skill) to produce the Evidence Pack report.

# Flunisolide: From Unspecified Original Indication to Atopic Eczema

## One-Sentence Summary

Flunisolide (DrugBank DB00180) is a glucocorticoid whose original approved indication is not recorded in the current dataset. The TxGNN model predicts it may be effective for **Atopic Eczema**, but this direction is currently supported by **0 clinical trials** and only **1 publication**, and that publication is an observational biomarker study rather than direct treatment evidence.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not specified in current dataset (data gap — no license/indication text available) |
| Predicted New Indication | Atopic Eczema |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L4 |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for flunisolide in this evidence pack, and its original approved indication is also unrecorded. Flunisolide is known generically as a corticosteroid-class compound; glucocorticoids as a class are widely used in dermatology and respiratory medicine for their anti-inflammatory and immunosuppressive effects, which is the most plausible pharmacological basis for a TxGNN-predicted link to an inflammatory skin condition such as atopic eczema.

That said, the single supporting reference (PMID 18926054) is not a treatment study of flunisolide in atopic eczema — it is a cross-sectional biomarker study measuring exhaled breath condensate cytokines and pH in children with asthma and atopic dermatitis, used to explore shared inflammatory pathways between the two conditions. It does not evaluate flunisolide's efficacy, safety, or dosing in atopic eczema. Corticosteroids used for atopic dermatitis in practice are typically topical formulations (e.g., fluocinolone), and there is no data here indicating flunisolide is used or studied in a topical form for this purpose.

In short, the mechanistic rationale (steroid class → anti-inflammatory effect on an inflammatory skin condition) is biologically plausible at the class level, but the specific evidence tying flunisolide itself to atopic eczema treatment is indirect and weak. This should be treated as a hypothesis-generating signal rather than a validated repurposing candidate.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [18926054](https://pubmed.ncbi.nlm.nih.gov/18926054/) | 2008 | Cross-sectional/Observational (biomarker study) | Allergy and Asthma Proceedings | Measured exhaled breath condensate cytokines and pH in children with asthma and atopic dermatitis; explores shared Th1/Th2/Treg inflammatory pathways and short-course inhaled corticosteroid effects on these biomarkers — not a direct efficacy study of flunisolide for atopic eczema. |

---

## US Market Information

Flunisolide currently holds no marketing authorization records in this dataset — market status is **Not Marketed**, with 0 total licenses. No NDA, product name, or approved-indication details are available to report.

---

## Safety Considerations

Please refer to the package insert for safety information.

*(Key warnings, contraindications, and drug-drug interaction data are all unavailable in the current dataset — TFDA label/warning data is flagged as a blocking data gap, DG001.)*

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
- The evidence for atopic eczema is limited to one indirect, non-treatment publication (L4, no clinical trials), and a blocking data gap (DG001: missing TFDA label warnings/contraindications) currently prevents even an initial (S1) safety assessment. Combined with the absence of original indication and mechanism-of-action data, there is insufficient basis to advance beyond a research hypothesis at this time.

**To proceed, the following is needed:**
- TFDA/FDA label data (warnings, contraindications) to clear the blocking safety data gap (DG001)
- Mechanism of action (MOA) data from DrugBank to support or refute the mechanistic rationale (DG002)
- Confirmation of flunisolide's original approved indication(s), which is currently unrecorded
- Additional direct clinical or preclinical evidence specifically evaluating flunisolide (rather than corticosteroids as a class) in atopic eczema/dermatitis
- Note: other TxGNN-predicted candidates for this drug (e.g., bronchitis, L3/S2) carry somewhat stronger — though still preliminary — evidence and may warrant separate evaluation
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

